A

Apellis Pharmaceuticals

Develops complement inhibition therapies for diseases

Director – SYFOVRE Market Access Strategy

Product MarketingConfirmed live in the last 24 hours
Full-timeCambridge, MA, USANo salary listed

About the Job

Requirements

  • A bachelor's degree is required.
  • At least 12 years of experience in U.S. market access, payer marketing, reimbursement, pricing and contracting, or related pharmaceutical or biotechnology work.
  • Demonstrated experience developing and executing market access strategies for specialty or physician-administered products.
  • Deep understanding of buy-and-bill reimbursement, including Medicare Part B, commercial payer dynamics, ASP-based reimbursement, provider economics, coding and payment, and site of care.
  • Experience in payer/provider marketing, pricing and contracting, and translating access dynamics into actionable customer strategies.
  • Ability to assess competitive market dynamics and develop strategies to protect or expand access.
  • Proven ability to lead complex cross-functional initiatives, analyze business issues, and influence senior stakeholders.

Responsibilities

  • Lead the integrated U.S. market access strategy for SYFOVRE and serve as the single point of accountability to the BNA Leadership Team for access performance, risks, and required actions.
  • Lead pricing and contracting strategies that balance patient access, provider economics, competitive positioning, and sustainable net revenue.
  • Lead payer and reimbursement marketing and optimize the buy-and-bill experience across coverage, coding, payment, acquisition economics, and operational barriers.
  • Monitor evolving retina market dynamics, including competitive products, biosimilars, payer utilization management, provider economics, ASP trends, reimbursement, and policy changes; translate insights into brand strategy and long-range planning.
  • Partner with Medical to identify evidence gaps and strengthen the SYFOVRE value proposition with payers and providers.
  • Partner with Payer Accounts, Field Reimbursement, Strategic Accounts, Trade & Distribution, and other cross-functional teams to execute customer strategies and ensure effective pull-through of access priorities.
  • Serve as a key member of the Retina and Nephrology/Hematology Access Strategy Leadership Team, ensuring market access considerations inform strategic and investment decisions.
  • Provide leadership and strategic direction across functions, driving alignment and accountability for critical SYFOVRE access priorities.
  • Manage a team focused on payer and reimbursement marketing strategy and tactics, pricing and contracting initiatives, and support for payer, strategic accounts, and reimbursement field teams.
  • Ensure access strategy is integrated with brand objectives and partner across MA&R, Medical, Finance, Trade & Distribution, and the SYFOVRE franchise to anticipate market changes, address access barriers, and align access strategy with business objectives.

Desired Qualifications

  • An MBA, MPH, or other advanced degree is preferred.
  • Experience in ophthalmology, retina, or another physician-administered specialty market, including Medicare Part B and ASP-based reimbursement.
  • Experience with retina practices, GPOs, health systems, specialty distributors, or other stakeholders in the buy-and-bill ecosystem.
  • Experience managing access for an established brand in a market facing biosimilar, generic, or other significant price-based competition.

About the Company

Apellis Pharmaceuticals

Develops complement inhibition therapies for diseases

Apellis Pharmaceuticals develops therapies that target the complement system, a part of the immune system involved in inflammation and disease. The company focuses on complement inhibition to treat rare and debilitating conditions with unmet medical needs. Its approach centers on therapies that precisely modulate the complement cascade to help patients. Apellis went public in 2017 to fund its research and development efforts, and in 2025 it formed a strategic partnership with Sobi to sell ex-US royalties on its drug Aspaveli for up to $300 million, providing capital and expanding global reach. Compared with competitors, Apellis pursues targeted complement modulation and leverages strategic partnerships and royalties to support its growth. The company's goal is to advance effective, targeted treatments that improve the lives of patients worldwide by addressing diseases driven by the complement system.

Company size
501-1,000
Company stage
IPO
Headquarters
Waltham, MA
Founded
2008

Recently Posted Jobs

Explore more opportunities at Apellis Pharmaceuticals

See more jobs